КЛИНИЧЕСКАЯ ЭФФЕКТИВНОСТЬ МОНОТЕРАПИИ ЗОФЕНОПРИЛОМ У БОЛЬНЫХ АГ С УЧЁТОМ С-344T ПОЛИМОРФНОГО МАРКЕРА ГЕНА CYP11B2

The aim of the present study was to evaluate antihypertensive, cardioprotective efficacy and clinical safety of 12-week Zofenopril monotherapy in association with the C-344T polymorphism of CYP11B2 gene in Uzbek hypertensive patients. Material and methods: In order to study prevalence of C-344T polymorphism of CYP11B2 gene there were selected 150 Uzbek hypertensive patients with Stage I–III of arterial hypertension (ESH/ESC, 2013), as well as 58 healthy Uzbeks in age from 30 to 70 years. The clinical efficacy of 12-week zofenopril monotherapy in association with the C-344T polymorphism of CYP11B2 gene was study in 39 ethnic Uzbek patients with untreated AH of Grade 1 and 2 (ESH/ESC, 2013). M- and B-mode echocardiographic examination was performed. Genotyping of C-344T polymorphism of CYP11B2 gene was determined by allele-specific oligonucleotide hybridization after PCR amplification and restriction digestion. Results and conclusion. The significant accumulation of T-allele of C-344T polymorphism of CYP11B2 gene among Uzbek hypertensive patients was revealed. On the basis of genetic models of study there was found tendency to associative link of T- allele of C-344T polymorphism of CYP11B2 gene with AH in Uzbeks. There was association of intensity of LVH and LVDD with carrying of TT-genotype. Results of our study showed that carrying of TT-genotype of CYP11B2 gene limited antihypertensive and cardioprotective efficacy of Zofenopril.